F.D.A. Delays Action on Closely Watched Alzheimer’s Drug

NYT HEALTH: F.D.A. Delays Action on Closely Watched Alzheimer’s Drug
By Pam Belluck
Section: Health
Source: New York Times
Published Date: March 8, 2024 at 02:00AM

Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.

Read more: https://www.nytimes.com/2024/03/08/health/alzheimers-drug-donanemab.html?partner=IFTTT